A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection
INFECTION with human immunodeficiency virus type 1 (HIV) causes chronic progressive immunologic dysfunction. 1 , 2 Although the precise mechanisms of HIV-induced immune defects remain to be elucidated, the development of immunologic dysfunction as a result of HIV infection is well documented. 1 2 3...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1991-06, Vol.324 (24), p.1677-1684 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1684 |
|---|---|
| container_issue | 24 |
| container_start_page | 1677 |
| container_title | The New England journal of medicine |
| container_volume | 324 |
| creator | Redfield, Robert R Birx, Deborah L Ketter, Nzeera Tramont, Edmund Polonis, Victoria Davis, Charles Brundage, John F Smith, Gale Johnson, Steven Fowler, Arnold Wierzba, Thomas Shafferman, Avigdor Volvovitz, Franklin Oster, Charles Burke, Donald S |
| description | INFECTION with human immunodeficiency virus type 1 (HIV) causes chronic progressive immunologic dysfunction.
1
,
2
Although the precise mechanisms of HIV-induced immune defects remain to be elucidated, the development of immunologic dysfunction as a result of HIV infection is well documented.
1
2
3
4
5
6
7
8
Longitudinal studies of HIV-infected cohorts have demonstrated a predictable rate of decline in the CD4 cell count and a relation between the CD4 cell count and survival.
3
,
4
,
9
10
11
12
Accordingly, HIV infection can be clinically classified into distinct prognostic stages on the basis of increasing degrees of immunologic dysfunction.
13
Immune responses to HIV antigens are elicited during natural infection, and these may be . . . |
| doi_str_mv | 10.1056/NEJM199106133242401 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15935563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15935563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-bd4557cb4ab761efae0d15cc9f23e26b47a03611dc317b6b250e3ce65b2be2713</originalsourceid><addsrcrecordid>eNp90d2K1DAUwPEgCo6rT-BNUPRmqebkq-3lsoy7I6sufuxtSdKTnQxtOtu0yjyKb2uWDgii5iYQfudP4BDyHNgbYEq__bh-_wHqGpgGIbjkksEDsgIlRCEl0w_JijFeFbKsxWPyJKUdywdkvSI_z-j11iSkG7r-brrZTGGIdPB02iL9YjxOB2piSzd9P8fhFmNwIT9lcGOcC3HxP8K0pZ_RDb3NT3Git3vQjIZIrzPAOKWFrM3YHejl3Jt4LLbocxGjO9CbMM6JbqJHdx99Sh550yV8drxPyLd366_nl8XVp4vN-dlV4aSUU2FbqVTprDS21IDeIGtBOVd7LpBrK0vDhAZonYDSassVQ-FQK8st8hLECXm9dPfjcDdjmpo-JIddZyIOc2pA1UIpLTJ88QfcDfMY898azkWtQJYso5f_QlBXQgpQVZWVWJQbh5RG9M1-DL0ZDw2w5n6jzV82mqdeHdsmOdP50UQX0u_RugItS57d6eL6PjURd_1_q78A0lOs8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983431588</pqid></control><display><type>article</type><title>A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection</title><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Redfield, Robert R ; Birx, Deborah L ; Ketter, Nzeera ; Tramont, Edmund ; Polonis, Victoria ; Davis, Charles ; Brundage, John F ; Smith, Gale ; Johnson, Steven ; Fowler, Arnold ; Wierzba, Thomas ; Shafferman, Avigdor ; Volvovitz, Franklin ; Oster, Charles ; Burke, Donald S</creator><creatorcontrib>Redfield, Robert R ; Birx, Deborah L ; Ketter, Nzeera ; Tramont, Edmund ; Polonis, Victoria ; Davis, Charles ; Brundage, John F ; Smith, Gale ; Johnson, Steven ; Fowler, Arnold ; Wierzba, Thomas ; Shafferman, Avigdor ; Volvovitz, Franklin ; Oster, Charles ; Burke, Donald S ; the Military Medical Consortium for Applied Retroviral Research</creatorcontrib><description>INFECTION with human immunodeficiency virus type 1 (HIV) causes chronic progressive immunologic dysfunction.
1
,
2
Although the precise mechanisms of HIV-induced immune defects remain to be elucidated, the development of immunologic dysfunction as a result of HIV infection is well documented.
1
2
3
4
5
6
7
8
Longitudinal studies of HIV-infected cohorts have demonstrated a predictable rate of decline in the CD4 cell count and a relation between the CD4 cell count and survival.
3
,
4
,
9
10
11
12
Accordingly, HIV infection can be clinically classified into distinct prognostic stages on the basis of increasing degrees of immunologic dysfunction.
13
Immune responses to HIV antigens are elicited during natural infection, and these may be . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199106133242401</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Antigens ; Biological and medical sciences ; Blood tests ; Candida albicans ; CD4 antigen ; Cell growth ; Cell-mediated immunity ; Drug dosages ; Epitopes ; Glycoprotein gp160 ; HIV ; Human immunodeficiency virus ; Humoral immunity ; Hypotheses ; Immune response (humoral) ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunogenicity ; Immunopathology ; Infections ; Lymphocytes ; Lymphocytes T ; Medical sciences ; Proteins ; Seroconversion ; Skin ; Tetanus ; Vaccines ; Viral envelope proteins</subject><ispartof>The New England journal of medicine, 1991-06, Vol.324 (24), p.1677-1684</ispartof><rights>1991 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society Jun 13, 1991</rights><rights>Copyright Massachusetts Medical Society, Publishing Division Jun 13, 1991</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-bd4557cb4ab761efae0d15cc9f23e26b47a03611dc317b6b250e3ce65b2be2713</citedby><cites>FETCH-LOGICAL-c444t-bd4557cb4ab761efae0d15cc9f23e26b47a03611dc317b6b250e3ce65b2be2713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199106133242401$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1983431588?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,2760,2761,26107,27928,27929,52386,54068,64389,64391,64393,72473</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19816472$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Redfield, Robert R</creatorcontrib><creatorcontrib>Birx, Deborah L</creatorcontrib><creatorcontrib>Ketter, Nzeera</creatorcontrib><creatorcontrib>Tramont, Edmund</creatorcontrib><creatorcontrib>Polonis, Victoria</creatorcontrib><creatorcontrib>Davis, Charles</creatorcontrib><creatorcontrib>Brundage, John F</creatorcontrib><creatorcontrib>Smith, Gale</creatorcontrib><creatorcontrib>Johnson, Steven</creatorcontrib><creatorcontrib>Fowler, Arnold</creatorcontrib><creatorcontrib>Wierzba, Thomas</creatorcontrib><creatorcontrib>Shafferman, Avigdor</creatorcontrib><creatorcontrib>Volvovitz, Franklin</creatorcontrib><creatorcontrib>Oster, Charles</creatorcontrib><creatorcontrib>Burke, Donald S</creatorcontrib><creatorcontrib>the Military Medical Consortium for Applied Retroviral Research</creatorcontrib><title>A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection</title><title>The New England journal of medicine</title><description>INFECTION with human immunodeficiency virus type 1 (HIV) causes chronic progressive immunologic dysfunction.
1
,
2
Although the precise mechanisms of HIV-induced immune defects remain to be elucidated, the development of immunologic dysfunction as a result of HIV infection is well documented.
1
2
3
4
5
6
7
8
Longitudinal studies of HIV-infected cohorts have demonstrated a predictable rate of decline in the CD4 cell count and a relation between the CD4 cell count and survival.
3
,
4
,
9
10
11
12
Accordingly, HIV infection can be clinically classified into distinct prognostic stages on the basis of increasing degrees of immunologic dysfunction.
13
Immune responses to HIV antigens are elicited during natural infection, and these may be . . .</description><subject>Antigens</subject><subject>Biological and medical sciences</subject><subject>Blood tests</subject><subject>Candida albicans</subject><subject>CD4 antigen</subject><subject>Cell growth</subject><subject>Cell-mediated immunity</subject><subject>Drug dosages</subject><subject>Epitopes</subject><subject>Glycoprotein gp160</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humoral immunity</subject><subject>Hypotheses</subject><subject>Immune response (humoral)</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunogenicity</subject><subject>Immunopathology</subject><subject>Infections</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medical sciences</subject><subject>Proteins</subject><subject>Seroconversion</subject><subject>Skin</subject><subject>Tetanus</subject><subject>Vaccines</subject><subject>Viral envelope proteins</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp90d2K1DAUwPEgCo6rT-BNUPRmqebkq-3lsoy7I6sufuxtSdKTnQxtOtu0yjyKb2uWDgii5iYQfudP4BDyHNgbYEq__bh-_wHqGpgGIbjkksEDsgIlRCEl0w_JijFeFbKsxWPyJKUdywdkvSI_z-j11iSkG7r-brrZTGGIdPB02iL9YjxOB2piSzd9P8fhFmNwIT9lcGOcC3HxP8K0pZ_RDb3NT3Git3vQjIZIrzPAOKWFrM3YHejl3Jt4LLbocxGjO9CbMM6JbqJHdx99Sh550yV8drxPyLd366_nl8XVp4vN-dlV4aSUU2FbqVTprDS21IDeIGtBOVd7LpBrK0vDhAZonYDSassVQ-FQK8st8hLECXm9dPfjcDdjmpo-JIddZyIOc2pA1UIpLTJ88QfcDfMY898azkWtQJYso5f_QlBXQgpQVZWVWJQbh5RG9M1-DL0ZDw2w5n6jzV82mqdeHdsmOdP50UQX0u_RugItS57d6eL6PjURd_1_q78A0lOs8g</recordid><startdate>19910613</startdate><enddate>19910613</enddate><creator>Redfield, Robert R</creator><creator>Birx, Deborah L</creator><creator>Ketter, Nzeera</creator><creator>Tramont, Edmund</creator><creator>Polonis, Victoria</creator><creator>Davis, Charles</creator><creator>Brundage, John F</creator><creator>Smith, Gale</creator><creator>Johnson, Steven</creator><creator>Fowler, Arnold</creator><creator>Wierzba, Thomas</creator><creator>Shafferman, Avigdor</creator><creator>Volvovitz, Franklin</creator><creator>Oster, Charles</creator><creator>Burke, Donald S</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19910613</creationdate><title>A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection</title><author>Redfield, Robert R ; Birx, Deborah L ; Ketter, Nzeera ; Tramont, Edmund ; Polonis, Victoria ; Davis, Charles ; Brundage, John F ; Smith, Gale ; Johnson, Steven ; Fowler, Arnold ; Wierzba, Thomas ; Shafferman, Avigdor ; Volvovitz, Franklin ; Oster, Charles ; Burke, Donald S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-bd4557cb4ab761efae0d15cc9f23e26b47a03611dc317b6b250e3ce65b2be2713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Antigens</topic><topic>Biological and medical sciences</topic><topic>Blood tests</topic><topic>Candida albicans</topic><topic>CD4 antigen</topic><topic>Cell growth</topic><topic>Cell-mediated immunity</topic><topic>Drug dosages</topic><topic>Epitopes</topic><topic>Glycoprotein gp160</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humoral immunity</topic><topic>Hypotheses</topic><topic>Immune response (humoral)</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunogenicity</topic><topic>Immunopathology</topic><topic>Infections</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medical sciences</topic><topic>Proteins</topic><topic>Seroconversion</topic><topic>Skin</topic><topic>Tetanus</topic><topic>Vaccines</topic><topic>Viral envelope proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Redfield, Robert R</creatorcontrib><creatorcontrib>Birx, Deborah L</creatorcontrib><creatorcontrib>Ketter, Nzeera</creatorcontrib><creatorcontrib>Tramont, Edmund</creatorcontrib><creatorcontrib>Polonis, Victoria</creatorcontrib><creatorcontrib>Davis, Charles</creatorcontrib><creatorcontrib>Brundage, John F</creatorcontrib><creatorcontrib>Smith, Gale</creatorcontrib><creatorcontrib>Johnson, Steven</creatorcontrib><creatorcontrib>Fowler, Arnold</creatorcontrib><creatorcontrib>Wierzba, Thomas</creatorcontrib><creatorcontrib>Shafferman, Avigdor</creatorcontrib><creatorcontrib>Volvovitz, Franklin</creatorcontrib><creatorcontrib>Oster, Charles</creatorcontrib><creatorcontrib>Burke, Donald S</creatorcontrib><creatorcontrib>the Military Medical Consortium for Applied Retroviral Research</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Redfield, Robert R</au><au>Birx, Deborah L</au><au>Ketter, Nzeera</au><au>Tramont, Edmund</au><au>Polonis, Victoria</au><au>Davis, Charles</au><au>Brundage, John F</au><au>Smith, Gale</au><au>Johnson, Steven</au><au>Fowler, Arnold</au><au>Wierzba, Thomas</au><au>Shafferman, Avigdor</au><au>Volvovitz, Franklin</au><au>Oster, Charles</au><au>Burke, Donald S</au><aucorp>the Military Medical Consortium for Applied Retroviral Research</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection</atitle><jtitle>The New England journal of medicine</jtitle><date>1991-06-13</date><risdate>1991</risdate><volume>324</volume><issue>24</issue><spage>1677</spage><epage>1684</epage><pages>1677-1684</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>INFECTION with human immunodeficiency virus type 1 (HIV) causes chronic progressive immunologic dysfunction.
1
,
2
Although the precise mechanisms of HIV-induced immune defects remain to be elucidated, the development of immunologic dysfunction as a result of HIV infection is well documented.
1
2
3
4
5
6
7
8
Longitudinal studies of HIV-infected cohorts have demonstrated a predictable rate of decline in the CD4 cell count and a relation between the CD4 cell count and survival.
3
,
4
,
9
10
11
12
Accordingly, HIV infection can be clinically classified into distinct prognostic stages on the basis of increasing degrees of immunologic dysfunction.
13
Immune responses to HIV antigens are elicited during natural infection, and these may be . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJM199106133242401</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1991-06, Vol.324 (24), p.1677-1684 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15935563 |
| source | EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antigens Biological and medical sciences Blood tests Candida albicans CD4 antigen Cell growth Cell-mediated immunity Drug dosages Epitopes Glycoprotein gp160 HIV Human immunodeficiency virus Humoral immunity Hypotheses Immune response (humoral) Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunogenicity Immunopathology Infections Lymphocytes Lymphocytes T Medical sciences Proteins Seroconversion Skin Tetanus Vaccines Viral envelope proteins |
| title | A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T15%3A15%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Evaluation%20of%20the%20Safety%20and%20Immunogenicity%20of%20Vaccination%20with%20Recombinant%20gp160%20in%20Patients%20with%20Early%20Human%20Immunodeficiency%20Virus%20Infection&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Redfield,%20Robert%20R&rft.aucorp=the%20Military%20Medical%20Consortium%20for%20Applied%20Retroviral%20Research&rft.date=1991-06-13&rft.volume=324&rft.issue=24&rft.spage=1677&rft.epage=1684&rft.pages=1677-1684&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199106133242401&rft_dat=%3Cproquest_cross%3E15935563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983431588&rft_id=info:pmid/&rfr_iscdi=true |